Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.75B P/E - EPS this Y 278.40% Ern Qtrly Grth -
Income -61.29M Forward P/E 45.63 EPS next Y 93.90% 50D Avg Chg 12.00%
Sales 726.44M PEG -0.07 EPS past 5Y - 200D Avg Chg 45.00%
Dividend N/A Price/Book 12.06 EPS next 5Y -357.00% 52W High Chg -14.00%
Recommedations 2.10 Quick Ratio 2.13 Shares Outstanding 164.77M 52W Low Chg 113.00%
Insider Own 0.49% ROA -6.86% Shares Float 109.87M Beta 0.39
Inst Own 99.56% ROE -14.73% Shares Shorted/Prior 11.20M/10.81M Price 29.20
Gross Margin 45.87% Profit Margin -8.44% Avg. Volume 1,634,129 Target Price 29.62
Oper. Margin 15.13% Earnings Date May 6 Volume 1,707,063 Change 0.90%
About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ACADIA Pharmaceuticals Inc. News
03:05 PM Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
04/11/24 3 Pharma Stocks to Sell in April Before They Crash & Burn
04/10/24 ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares
04/02/24 Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
04/01/24 Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
03/28/24 ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares
03/15/24 Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/14/24 3 Pharma Stocks to Sell in March Before They Crash & Burn
03/13/24 Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
03/12/24 Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study
03/11/24 UPDATE 2-Acadia to stop trials of antipsychotic drug after it fails schizophrenia study
03/11/24 Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
03/01/24 Analysts Have Made A Financial Statement On ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Yearly Report
02/29/24 Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
02/29/24 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2023 Earnings Call Transcript
02/29/24 ACADIA Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
02/28/24 Acadia Stock Dives As Unexpected Seasonality Rocks Its Most High-Profile Launch
02/28/24 Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down
02/27/24 Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
02/27/24 ACADIA Pharmaceuticals Inc. Reports Strong Revenue Growth in Q4 and Full Year 2023
ACAD Chatroom

User Image Downsiderisk Posted - 5 hours ago

$ACAD a TON of rumors swirling Steve Davis and Acadia are on their 9th life! This seems fitting seeing they've went 0-9 on approvals the last 8 years. Let's sum this titanic up: Daypew sales are tanking and reps are at the movies by 11am everyday. Not surprising seeing its RARE disease. Nuplazid has plateaued and no new growth over the last 6 years with a flat trend line. let's face it the only reason this dumpster fire is still going is because they thought at least 1 or 2 approvals would happen but the well is dry for old Stevie boy. No potential launch for another 4-5 years and my guess is that won't get approved either. This is why this stock is at 16 after 10 years!

User Image DonCorleone77 Posted - 6 hours ago

$ACAD Acadia Pharmaceuticals to present trofinetide findings in Rett syndrome at AAN The company states: "Acadia Pharmaceuticals announced that two oral presentations featuring DAYBUE findings in Rett syndrome will be presented at the American Academy of Neurology 2024 annual meeting, being held this week in Denver, CO. The presentations include outcomes from the DAFFODIL(TM), a Phase 2/3 open-label study evaluating the safety, tolerability and exploratory efficacy of DAYBUE in girls aged two to four living with Rett syndrome, as well as findings from exit interviews with caregivers of individuals living with Rett syndrome who participated in the LAVENDER(TM), LILAC(TM), LILAC-2(TM) and DAFFODIL studies."

User Image Stock_Titan Posted - 6 hours ago

$ACAD Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting https://www.stocktitan.net/news/ACAD/acadia-pharmaceuticals-presents-new-daybue-trofinetide-clinical-data-z5r8wqk37lkp.html

User Image Tom1985IT Posted - 15 hours ago

$ACAD this stock has been only going one way since 6 months ↘️

User Image JRquiz Posted - 22 hours ago

$ACAD Potential entry point emerging here 👀

User Image Downsiderisk Posted - 2 days ago

$ACAD the Uncle is always right I guess. This guys has you bulls by the balls! This stock is as dead as Zeus's portfolio!

User Image SkSk_ Posted - 2 days ago

$ACAD undervalued as heck going into ER. going to wait a few more days for more geopolitical bleeding then snag some cheap calls to cover may ER.

User Image Downsiderisk Posted - 2 days ago

$ACAD

User Image SBL71 Posted - 2 days ago

$ACAD nice little write up on the Bakers this AM in WSJ. Interesting they mentioned that the majority of the SGeN money was distributed back to investors as the Bakers didn’t feel there was strong enough new investment out there to deploy cash into. Hmmm.

User Image HorizonBull Posted - 5 days ago

$ACAD 30+ after ER in may

User Image GI197845 Posted - 5 days ago

$ACAD Wow, a new 52 week low after hours at 16.84. Did insurance stop reimbursement payments for the extremely expensive Nuplazid and Trofinetide? Wait, I know, hire more executives and have a stock inducement, or a shelf offering, or a reverse split!

User Image Nosh Posted - 5 days ago

$ACAD And another block to clean up the stream...99% chance the same person with two accounts.

User Image Downsiderisk Posted - 5 days ago

$ACAD stock to $10

User Image Nosh Posted - 5 days ago

$ACAD Looking for entry at 15.50 area as support is broken...it happens it happens.

User Image Nosh Posted - 5 days ago

$ACAD Went through the stream and blocked this guy...constant spam on the board.

User Image VolumePrice Posted - 5 days ago

$XERS $ACAD I am buying

User Image zeustony88 Posted - 5 days ago

$ACAD

User Image BobBijawk Posted - 5 days ago

$IBRX I am liking an entry point on $acad . Patent protectoin on parkinons dementia for 10 more years and dayblue is the only approved drug for rhett syndrome. also a phase 3 in a ultra orphan that will be up for approval on the back end of 24 . And a phase 2 in alzheimers psychosis that if approved woudl garner a increase in stock price up to 3 fold of todays price. Annual EPS around 1.00 and revnues in the billion dollar per year range. 17 per share is a steal.

User Image Downsiderisk Posted - 6 days ago

$ACAD

User Image Jiffy485 Posted - 6 days ago

$ACAD Davis desperately needs to go

User Image SBL71 Posted - 1 week ago

$ACAD @GI197845 I have seen you make remarks about this Rx before...what I think might be helpful is if you take 1 minute and think about why this Rx is important. We all have someone in our lives that has faced challenges-cancer, immune disease, cardio issue, ect ect...Rett is felt in primary young girls. Maybe just step back for one minute...before your next slap at this Rx/company and think about how lucky you are not to have any young female in your world yet affected by this disease state and what a blessing it must be to have a Tx available, even in the presence of some minor and controllable side effects. 1 minute.

User Image GI197845 Posted - 1 week ago

$ACAD

User Image erevnon Posted - 1 week ago

Cantor Fitzgerald reiterates ACADIA Pharmaceuticals $ACAD at Overweight and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

User Image insiderbuyingselling Posted - 1 week ago

$ACAD new insider selling: 26574 shares. http://insiderbuyingselling.com/?t=ACAD

User Image insiderbuyingselling Posted - 1 week ago

$ACAD new insider selling: 2568 shares. http://insiderbuyingselling.com/?t=ACAD

User Image GI197845 Posted - 1 week ago

$ACAD Rah! Rah! Rah! The 5 million dollar research center in Sweden is paying dividends! I hope the female-children-patients are being helped by Daybue, instead of only spraying out nasty diarrhea!

User Image erevnon Posted - 1 week ago

Needham reiterates ACADIA Pharmaceuticals $ACAD at Buy and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

User Image BobBijawk Posted - 1 week ago

$ACAD Stock has swung lower but should bounce back into 20s in next 6 month.this is quite the buying oppurtunity long term. anything south of 20 is a solid investment in my opinion given the two apporved drugs and the late stage phase 3 . Add to the the phase two for dementia this could be easily 50 dollars if both endup approved by FDA.

User Image HorizonBull Posted - 1 week ago

$ACAD BBs have huge load on this

User Image HorizonBull Posted - 1 week ago

$ACAD over 1B revenue in next ER. Easy 30+. accumulation. Huge gain

Analyst Ratings
Cantor Fitzgerald Overweight Apr 10, 24
Needham Buy Apr 9, 24
JP Morgan Overweight Mar 25, 24
Morgan Stanley Overweight Mar 13, 24
Citigroup Buy Mar 12, 24
RBC Capital Outperform Mar 12, 24
Cantor Fitzgerald Overweight Mar 12, 24
Oppenheimer Perform Mar 12, 24
Baird Outperform Mar 12, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
DAVIS STEPHEN CEO CEO Jan 06 Sell 29.96 3,732 111,811 96,521 01/09/24
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Jan 06 Sell 29.96 731 21,901 30,949 01/09/24
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Jan 06 Sell 29.96 590 17,676 46,901 01/09/24
Kihara James Principal Accounting.. Principal Accounting Officer Dec 15 Sell 28.30 2,000 56,600 11,025 12/15/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Nov 17 Sell 22.64 4,960 112,294 30,393 11/21/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Nov 17 Sell 22.64 5,108 115,645 20,486 11/21/23
Kihara James Principal Accounting.. Principal Accounting Officer Nov 17 Sell 22.64 1,985 44,940 13,025 11/21/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Oct 05 Sell 21.96 16,369 359,463 45,857 10/06/23
DAVIS STEPHEN CEO CEO Oct 05 Sell 21.96 51,563 1,132,323 89,131 10/06/23
Kihara James Principal Accounting.. Principal Accounting Officer Sep 15 Sell 25.88 2,000 51,760 10,778 09/19/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Aug 21 Sell 28.997 10,000 289,970 15,682 08/23/23
DAVIS STEPHEN CEO CEO Jul 14 Option 20.77 100,000 2,077,000 136,695 07/18/23
DAVIS STEPHEN CEO CEO Jul 14 Sell 30.04 100,000 3,004,000 36,695 07/18/23
DAVIS STEPHEN CEO CEO Jul 11 Sell 25.03 71,602 1,792,198 36,695 07/13/23
Brege Laura Director Director Jun 12 Sell 24.868 4,500 111,906 13,502 06/14/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Jun 08 Sell 25.02 974 24,369 22,824 06/12/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Jun 08 Option 0 1,893 23,798 06/12/23
BAKER BROS. ADVISORS LP Director Director May 22 Buy 25.22 896,522 22,610,285 39,317,673 05/24/23
BAKER BROS. ADVISORS LP Director Director May 22 Option 17.01 25,000 425,250 38,620,261 05/24/23
Kihara James Principal Accounting.. Principal Accounting Officer May 17 Sell 22.5 5,947 133,808 11,144 05/19/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer May 17 Sell 22.5 15,310 344,475 21,905 05/19/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial May 17 Sell 22.5 14,869 334,552 24,356 05/19/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Apr 29 Sell 21.18 917 19,422 25,513 05/02/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Apr 29 Sell 21.18 548 11,607 9,487 05/02/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Apr 29 Option 0 1,567 10,035 05/02/23
DAVIS STEPHEN CEO CEO Apr 29 Sell 21.18 7,806 165,331 108,297 05/02/23
DAVIS STEPHEN CEO CEO Apr 29 Option 0 15,625 116,103 05/02/23
Kihara James Principal Accounting.. Principal Accounting Officer Apr 07 Sell 18.14 523 9,487 5,197 04/11/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Apr 05 Sell 18.16 1,751 31,798 8,468 04/07/23
Kihara James Principal Accounting.. Principal Accounting Officer Apr 05 Sell 18.16 701 12,730 4,231 04/07/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Apr 05 Sell 18.16 1,916 34,795 7,477 04/07/23
DAVIS STEPHEN CEO CEO Apr 05 Sell 18.16 8,582 155,849 100,478 04/07/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Apr 05 Sell 18.16 1,456 26,441 23,425 04/07/23
Kihara James Principal Accounting.. Principal Accounting Officer Feb 23 Sell 18.78 350 6,573 2,923 02/27/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Feb 23 Sell 18.78 577 10,836 4,118 02/27/23
DAVIS STEPHEN CEO CEO Feb 23 Sell 18.78 3,851 72,322 91,727 02/27/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Feb 23 Sell 18.78 803 15,080 20,108 02/27/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Feb 23 Sell 18.78 461 8,658 5,195 02/27/23
BAKER BROS. ADVISORS LP Director Director Jan 12 Option 5.22 30,000 156,600 38,484,981 01/17/23
DAVIS STEPHEN CEO CEO Jan 06 Sell 17.13 3,904 66,876 84,633 01/10/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Jan 06 Sell 17.13 532 9,113 4,549 01/10/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Jan 06 Sell 17.13 589 10,090 18,697 01/10/23
Stankovic Srdjan R. President President Oct 15 Sell 15.81 1,326 20,964 56,831 10/18/22
DAVIS STEPHEN CEO CEO Oct 15 Sell 15.81 2,804 44,331 79,009 10/18/22
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Jun 08 Option 0 1,893 3,995 06/10/22
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Jun 08 Sell 17.91 653 11,695 3,342 06/10/22
DAVIS STEPHEN CEO CEO Apr 29 Sell 18.18 5,483 99,681 75,875 05/03/22
Stankovic Srdjan R. President President Apr 29 Sell 18.18 2,865 52,086 55,188 05/03/22
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Apr 29 Sell 18.18 894 16,253 16,742 05/03/22
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Apr 29 Sell 18.18 552 10,035 3,437 05/03/22